摘要
目的探讨舍曲林联合小剂量奥氮平治疗躯体形式障碍的临床疗效及安全性。方法将70例躯体形式障碍患者随机分为两组各35例，研究组口服舍曲林联合小剂量奥氮平治疗，对照组单用舍曲林治疗，两组均施以健康教育、认知指导、支持性心理治疗，观察8w。于治疗前及治疗1w、2w、4w、8w末采用症状自评量表评定两组总分、躯体化、抑郁、焦虑因子项目的变化。结果两组治疗各时段症状自评量表总分、躯体化、抑郁、焦虑因子分均较治疗前显著下降（P〈0．01），但同期研究组均较对照组下降显著（P〈0．05或0．01）；两组不良反应均较轻微。结论舍曲林联合小剂量奥氮平并辅以健康教育、认知指导、支持性心理治疗躯体形式障碍，能有效改善患者的整体状态、躯体症状、焦虑抑郁症状，且安全性高，显著优于单用舍曲林治疗。
Objective To explore the clinical efficacy and safety of sertraline combined with low dose olanzapine in somatoform disorder（SD）. Methods 70 SD patients were randomly divided into two groups of 35 ones each, research group took orally sertraline combined with low dose olanzapine and control group did sertraline only for 8 weeks. clinical efficacies were assessed according to total scores of the Symptom Checklist-90（SCL-90）, such fac tor item as somzatization,depression and anxiety before treatment and at the end of the 1st, 2nd, 4th and 8th week. Results After treatment, total, somatization, depression and anxiety score of the SCL-90 of both groups lowered more significantly compared with pretreatment（P〈0.01） ; those did more significantly in the research than in the control group in the corresponding time period（P〈0.05 or 0.01）. Adverse reactions were mild. Conclusion On the basis of the given health eudcation, cognition guidance and supportive psychotherapy, sertraline combined with low dose olanzapine can effectively improve overall status, somatization and anxiety depression symptoms and has higher safety compred with sertraline only in the treatment of somatoform disorder .
出处
《临床心身疾病杂志》
CAS
2009年第6期481-482,共2页
Journal of Clinical Psychosomatic Diseases
